Civilization launches with a $1M pilot fund to back innovators in genomics + diagnostics, digital health and synthetic biology (including gene + cell therapies).
Rocket Pharma lists on Nasdaq, and a unicorn is born. Rocket has multiple first-in-class gene therapies in clinical trials to cure devastating inherited diseases.
Singular Bio is acquired by Invitae to help increase access to accurate genetic screening in early pregnancy.
Civilization raises $35M second fund to lead pre/seed investments just as the world deals with the COVID pandemic and vaccine efforts begin.
Lemonaid Health - a pioneer in telemedicine - joins forces with genetic testing leader 23andme in a landmark $400M acquisition.
Gene editing pioneer Rewrite - with CV as its founding investor - is acquired by Intellia for $200M in a key move for the industry.
Civilization raises its Opportunity Fund to back founders as they scale, bringing our total capital under management to over $100M.
Fluent BioSciences is acquired by Illumina in a pivotal move to strengthen its single-cell analysis platform.
Omada Health completes its public listing in seminal event for the health tech sector. Omada tackles chronic diseases impacting >150M Americans with its unique digital programs that have been adopted by thousands of organizations.
.png)
BilliontoOne completes its public listing at a $5 Billion valuation. BilliontoOne has developed an ultra-sensitive molecular diagnostics platform that is transforming prenatal and cancer care with over 1M tests processed.
.png)
.png)
.png)
